loading page

Transcriptomic insights into the development and therapy of breast cancer via the ncRNA-mediated ceRNA regulation network
  • Jim Al Khaled
Jim Al Khaled
Department of Biology, Alexanderia University

Corresponding Author:[email protected]

Author Profile


Several studies, made possible by the rapid development of next-generation sequencing technology, have shown that ncRNAs can act as competitive endogenous RNAs (ceRNAs) and are involved in a variety of biological processes, including the proliferation, differentiation, apoptosis, and migration of breast cancer (BC) cells, playing an important role in BC progression as a molecular target for its diagnosis, treatment, prognosis, and differentiation of subtypes and age groups of BC patients. This study screened and ranked the sequencing analysis and experimental verification conclusions of BC-related ceRNAs based on the description of ceRNA-related biological functions and found that the ncRNAs mediated ceRNA networks can promote the development of BC by promoting the expression of genes related to BC proliferation, drug resistance, and apoptosis; inducing the production of epithelial-mesenchymal transition (EMT) to promote metastasis; and activating cancer-related microRNAs. 1. Background Breast cancer (BC) is characterized by a wide range of phenotypes and genetic backgrounds. Surgery, radiation therapy, and chemotherapy are all often used to treat BC; nevertheless, the disease is difficult to cure since it frequently returns, spreads to other parts of the body, and develops resistance to drugs. To better the clinical treatment efficacy, early diagnosis rate, and prognosis of BC patients, it is crucial to identify novel therapeutic targets and diagnostic and prognostic biomarkers [1, 2, 3, 4]. Endogenous non-coding RNAs (ncRNAs) have garnered a lot of attention due to their regulatory roles in a wide range of biological processes, and their discovery has coincided with the gradual unveiling of complex genetic changes in BC made possible by the rapid development of transcriptomics and the cross-application of bioinformatics and big data science. Their identification has also considerably boosted efforts to identify therapeutic targets unique to BC. The mechanism of action of these recently found molecules in the process of BC remains unknown and is not able to give support for the diagnosis or treatment of BC, despite the fact that tremendous progress has been achieved in the creation of therapeutic methods and medications targeting BC [5]. Therefore, there has been a lot of effort put into trying to figure out how these ncRNAs are regulated both pre-and post-transcriptionally. Studies have demonstrated that ncRNAs, such as long non-coding RNAs (lncRNAs), circulatory RNAs (circRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) are improperly produced in a range of malignancies, including BC [6], and play a significant role in post-transcriptional regulation [7]. In addition, these compounds are associated with BC development, spread, and resistance to treatment [8]. Nonetheless, they have further use as indicators for BC patient prognosis, categorization, and staging [9]. As further research has shown [10],